Pointing to a "brand-new ball game" with vasodilator Orenitram (treprostinil extended-release tablets) in pulmonary arterial hypertension (PAH) and "tough competition" in the prostacyclin receptor agonist Uptravi (selexipag) from Actelion Ltd., United Therapeutics Inc. CEO Martine Rothblatt said that being able to promote her firm's therapy for reduction in morbidity and mortality – as well as improvements in exercise, as the label now proclaims – could boost sales.